Cell Free DNA; Biomarker; Laboratory; Sequencing; Break-through

2B - Genomics and Beyond: Novel Applications to Transform Healthcare
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Monday, October 9
1:20 PM - 2:50 PM

New genomic technologies are being developed that have the capability of totally transforming clinical practice. Much of what has been driving this has been advances in DNA sequencing, but there are additional technologies and applications that could also drive dramatic advances in the clinic. During this session, some of the most exciting, novel, and potentially transformative applications will be discussed. This will include the use of cell-free DNA as a biomarker in transplantation, epigenetic modifications in cell-free DNA as markers for cardiovascular disease, genomic approaches to discover and characterize drug targets in cardiovascular medicine, and DNA methylation markers for the early detection of cancer.

Learning Objectives:

Linnea Baudhuin

Associate Professor of Laboratory Medicine
Mayo Clinic

Linnea M. Baudhuin, PhD, is Associate Professor of Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, MN, USA. Dr. Baudhuin is co-director of the Personalized Genomics Laboratory and the Clinical Genome Sequencing Laboratory at Mayo Clinic. Dr. Baudhuin received her Ph.D. in Clinical Chemistry from Cleveland State University in conjunction with the Cleveland Clinic. She then completed fellowships in Clinical Chemistry and Clinical Molecular Genetics at Mayo Clinic. She is board certified in Clinical Molecular Genetics by the American Board of Medical Genetics and Genomics. Dr. Baudhuin’s clinical and research interests are related to Personalized Medicine and lie primarily in the areas of cardiovascular-related inherited disorders, pharmacogenomics, and next-generation sequencing.


Send Email for Linnea Baudhuin

Erik Ingelsson

Professor of Medicine
Stanford University

Erik Ingelsson, MD, PhD is Professor of Medicine at Stanford University. His main area of interest is the link between metabolic disturbances, such as obesity and insulin resistance, and the development of subclinical and clinical cardiovascular disease. His research is translational and interdisciplinary, combining methods from the molecular epidemiology field (genomic, metabolomic, transcriptomic, epigenomic and proteomic profiling in large population-based studies) with in-vivo and in- vitro work. This allows new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel targets for drug development.
Dr. Inglesson has had a leading role in many of the large efforts identifying new loci associated with cardiovascular and metabolic traits. He also has extensive experience from research on biomarkers and -omics methods, including development and use of prediction metrics and Mendelian randomization. He has served as PI of numerous –omics efforts in several Swedish cohort studies, including ULSAM, PIVUS, TwinGene and EpiHealth. Since 2014 and on, he has also built a team working with characterization of loci established in GWAS using different functional model systems. He has published over 240 peer-reviewed publications, of which >50 in journals with impact factor over 30. Before relocating to the U.S, he was Professor of Cardiovascular Epidemiology at Karolinska Institutet, Stockholm, Sweden (2010-2013) and Professor of Molecular Epidemiology at Uppsala University (2013-2016). He has been very successful in obtaining extramural funding, and has won many prestigious awards and grants, such as the AHA Trudy Bush Fellowship for Cardiovascular Research in Women’s Health, ERC starting grant, Wallenberg Academy Fellow and the Göran Gustafsson Prize in Medicine in 2015 (to the most successful medical researcher in Sweden under age 45).


Send Email for Erik Ingelsson

John Kisiel

Assistant Professor of Medicine
Mayo Clinic

John Kisiel, MD, of Mayo Clinic in Rochester, Minnesota, is Assistant Professor of Medicine and a Consultant in the Division of Gastroenterology and Hepatology. Dr. Kisiel received his MD from the University of Illinois; he completed his internal medicine & chief medicine residencies, and GI neoplasia & gastroenterology fellowships, as well as a masters degree in Clinical & Translational Research, at the Mayo School of Graduate Medical Education.
As a researcher in the GI Cancer Molecular Diagnostics laboratory, his work is focused on the discovery and clinical development of non-invasive biomarkers for the detection of colorectal, hepatobiliary and pancreatic cancers.
Dr. Kisiel is a member of the Mayo Clinic Center for Individualized Medicine Epigenomic Scientific Committee and Epigenomic Advisory Group and has an active clinical practice in inflammatory bowel disease and gastrointestinal endoscopy.


Send Email for John Kisiel

Steven C. Greenway

Assistant Professor
University of Calgary

Steven C Greenway, MSc, MD, FRCPC is a pediatric cardiologist and clinician-investigator in the Section of Cardiology at the Alberta Children's Hospital and an assistant professor in the Departments of Paediatrics, Cardiac Sciences and Biochemistry & Molecular Biology at the University of Calgary in Calgary, Alberta, Canada. He is a member of the Alberta Children's Hospital Research Institute and the Libin Cardiovascular Institute of Alberta. After completing an MSc degree in the laboratory of Dr Kenneth Storey at Carleton University he completed medical school at the University of Manitoba. Residency in Paediatrics and fellowships in Pediatric Cardiology and Heart Function and Transplantation were completed at The Hospital for Sick Children in Toronto. Clinical training was interrupted by a postdoctoral fellowship supported by the Pediatric Scientist Development Program in the Seidman laboratory at Harvard Medical School. Dr Greenway has been in Calgary since 2012 with research interests in translational genomics.


Send Email for Steven Greenway


2B - Genomics and Beyond: Novel Applications to Transform Healthcare
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Genomics and Beyond: Novel Applications to Transform Healthcare
CME (AMA PRA Category 1 Credits™) 1.5; CEU (NSGC Category 1) 0.15; Attendance CEU 1.5